DK1802749T3 - KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser - Google Patents
KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelserInfo
- Publication number
- DK1802749T3 DK1802749T3 DK05797320.8T DK05797320T DK1802749T3 DK 1802749 T3 DK1802749 T3 DK 1802749T3 DK 05797320 T DK05797320 T DK 05797320T DK 1802749 T3 DK1802749 T3 DK 1802749T3
- Authority
- DK
- Denmark
- Prior art keywords
- kaspp
- lrrk2
- gene
- preparation
- detection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62089304P | 2004-10-21 | 2004-10-21 | |
US62116904P | 2004-10-22 | 2004-10-22 | |
PCT/EP2005/010428 WO2006045392A2 (en) | 2004-10-21 | 2005-09-27 | Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1802749T3 true DK1802749T3 (da) | 2012-11-26 |
Family
ID=35965998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05797320.8T DK1802749T3 (da) | 2004-10-21 | 2005-09-27 | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser |
Country Status (7)
Country | Link |
---|---|
US (2) | US8029986B2 (da) |
EP (2) | EP1802749B1 (da) |
AU (1) | AU2005299089B2 (da) |
CA (1) | CA2584489C (da) |
DK (1) | DK1802749T3 (da) |
ES (1) | ES2393926T3 (da) |
WO (1) | WO2006045392A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO323175B1 (no) | 2004-12-23 | 2007-01-15 | Jan O Aasly | Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme |
US20100035251A1 (en) * | 2006-06-20 | 2010-02-11 | Yunsheng He | BioMarkers for the Progression of Alzheimer's Disease |
US8206942B2 (en) * | 2007-04-05 | 2012-06-26 | Medical Research Council | Methods of identifying LRRK2 inhibitors |
WO2009005730A1 (en) * | 2007-06-27 | 2009-01-08 | Cornell University | Transgenic animal models of parkinson's disease |
EP2321417B1 (en) * | 2008-08-20 | 2015-07-15 | Brainco Biopharma, S.L. | Stxbp1 as psychiatric biomarker in murine model system and its uses |
US20100175140A1 (en) * | 2008-12-19 | 2010-07-08 | The Johns Hopkins University | Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies |
EP2611772B1 (en) | 2010-09-02 | 2014-09-24 | GlaxoSmithKline Intellectual Property Development Limited | 2-(benzyloxy)benzamides as lrrk2 kinase inhibitors |
MX342177B (es) | 2011-09-30 | 2016-09-20 | Ipsen Pharma Sas | Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica. |
EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
MA39219B1 (fr) | 2014-01-29 | 2018-11-30 | Glaxosmithkline Ip Dev Ltd | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique |
WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
AU2015316801B2 (en) | 2014-09-17 | 2019-03-07 | Oncodesign S.A. | Macrocyclic LRRK2 kinase inhibitors |
KR102161364B1 (ko) | 2015-09-14 | 2020-09-29 | 화이자 인코포레이티드 | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 |
US10907160B2 (en) | 2016-01-05 | 2021-02-02 | Ionis Pharmaceuticals, Inc. | Methods for reducing LRRK2 expression |
CA3069554A1 (en) | 2017-07-14 | 2019-01-17 | Glaxosmithkline Intellectual Property Development Limited | Inhibitors of leucine rich repeat kinase 2 |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
JPH08512300A (ja) * | 1993-07-10 | 1996-12-24 | バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング | ニューロン損傷、変性及び細胞壊死の予防及び/又は治療、並びに腫瘍の治療を目的とするアンチセンス核酸を含む医薬用組成物 |
NZ502323A (en) | 1996-06-04 | 2001-09-28 | Univ Utah Res Found | Monitoring a fluorescence energy transfer pair during hybridization of first probe labelled with fluorescein to second probe labelled with Cy5 or Cy5.5 |
AU2002327419A1 (en) * | 2001-08-02 | 2003-02-17 | Incyte Genomics, Inc. | Kinases and phosphatases |
WO2003101283A2 (en) * | 2002-06-04 | 2003-12-11 | Incyte Corporation | Diagnostics markers for lung cancer |
US20040197792A1 (en) * | 2002-07-15 | 2004-10-07 | Sugen, Inc. | Novel Kinases |
WO2004023973A2 (en) * | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
-
2005
- 2005-09-27 ES ES05797320T patent/ES2393926T3/es active Active
- 2005-09-27 DK DK05797320.8T patent/DK1802749T3/da active
- 2005-09-27 US US11/665,875 patent/US8029986B2/en not_active Expired - Fee Related
- 2005-09-27 EP EP05797320A patent/EP1802749B1/en not_active Not-in-force
- 2005-09-27 EP EP10014786.7A patent/EP2316927B1/en not_active Not-in-force
- 2005-09-27 WO PCT/EP2005/010428 patent/WO2006045392A2/en active Application Filing
- 2005-09-27 CA CA2584489A patent/CA2584489C/en not_active Expired - Fee Related
- 2005-09-27 AU AU2005299089A patent/AU2005299089B2/en not_active Ceased
-
2011
- 2011-08-26 US US13/219,131 patent/US8409809B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2005299089A1 (en) | 2006-05-04 |
WO2006045392A3 (en) | 2006-08-10 |
AU2005299089B2 (en) | 2011-08-18 |
CA2584489A1 (en) | 2006-05-04 |
US20120035072A1 (en) | 2012-02-09 |
EP2316927A2 (en) | 2011-05-04 |
EP2316927A3 (en) | 2011-10-19 |
US8409809B2 (en) | 2013-04-02 |
EP1802749B1 (en) | 2012-08-22 |
EP2316927B1 (en) | 2014-11-05 |
ES2393926T3 (es) | 2013-01-02 |
US8029986B2 (en) | 2011-10-04 |
EP1802749A2 (en) | 2007-07-04 |
WO2006045392A2 (en) | 2006-05-04 |
US20100235933A1 (en) | 2010-09-16 |
CA2584489C (en) | 2014-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1802749T3 (da) | KASPP (LRRK2)-gen, dets fremstilling og anvendelse til påvisning og behandling af neurodegenerative lidelser | |
DK1663978T3 (da) | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser | |
DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
DK1812110T3 (da) | Apparat til behandling af dermatologiske lidelser | |
DK2878297T3 (da) | Lægemidler til behandling og forebyggelse af fibrotiske sygdomme | |
NO20055686L (no) | Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav. | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
DK2084151T3 (da) | Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme | |
DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
DK1928438T3 (da) | Anvendelse af ibudilast til behandling af stofafhængighed | |
DK2617714T3 (da) | Kemiske derivater af jasmonat, farmaceutiske præparater og fremgangsmåder til anvendelse deraf | |
DK1888294T3 (da) | Fremgangsmåde til hårdlodning af artikler af rustfrit stål | |
DK2120604T3 (da) | Fremgangsmåde til fraktionering af havre, produkter derved opnået, og anvendelser deraf | |
DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
DK1685834T3 (da) | Anvendelse af pinolensyre til behandling af obesitet | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
DK2109602T3 (da) | Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner | |
DK1740197T3 (da) | Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki | |
DK2044076T3 (da) | Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden | |
DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
DK2057153T3 (da) | (3-aryl-piperazin-1-yl)-derivater af 6,7 dialkoxyquinazolin, 6,7- dialkoxyphtalazin og 6,7-dialkoxyisoquinolin | |
DK1916995T4 (da) | Ph-styret, pulserende indgivelsessystem, fremgangsmåder til fremstilling og anvendelse deraf | |
DK1765355T3 (da) | Benzoxazin til behandling af luftvejslidelser |